ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions
View by Date
Jump to:  View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 0367
    Can Belonging to an AxSpA Patient Organization Be Associated with Benefits to Its Members? Results from the European Map of Axial Spondyloarthritis (EMAS)
  • Abstract Number: 1840
    Can Dual-energy CT Lung Perfusion Detect Abnormalities at the Level of Lung Circulation in Systemic Sclerosis (SSc) ? Preliminary Experience in 101 Patients
  • Abstract Number: 0257
    Can We Assess Disability in Juvenile Idiopathic Arthritis with Two Simple Questions? Results from the CAPRI Registry
  • Abstract Number: 0422
    Cancer in Patients with ANCA-associated Vasculitis: Which Came First, the Chicken or the Egg?
  • Abstract Number: 1456
    Cannabidiol Treatment in Hand Osteoarthritis and Psoriatic Arthritis – A Randomized, Double-blind Placebo-controlled Trial
  • Abstract Number: 0162
    Cardiac Magnetic Resonance Imaging for Guiding Decision-making on Treatment Duration: Data from RHAPSODY, a Phase 3 Clinical Trial of Rilonacept in Recurrent Pericarditis
  • Abstract Number: 0083
    Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome
  • Abstract Number: 1093
    Cardiovascular and Lipid Biomarker Distributions in Inflammatory Arthritis
  • Abstract Number: 0286
    Cardiovascular Disease Risk in Inflammatory Arthritis Patients Still Substantially Elevated in 2020
  • Abstract Number: 0679
    Cardiovascular Risk Associated with Treatment of Allopurinol and Benzbromarone in Patients with Gout
  • Abstract Number: 0708
    Cardiovascular Risk in Myositis Patients Compared to General Population – Preliminary Data from a Single-centre Cross-sectional Study
  • Abstract Number: 0283
    Cardiovascular Risk Management in Patients with Rheumatoid Arthritis: A Single-centered Cross-sectional Study
  • Abstract Number: L11
    Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study
  • Abstract Number: 1319
    Cardiovascular Risk Reclassification According to Six Traditional Cardiovascular Risk Algorithms and a Carotid Ultrasound in Psoriatic Arthritis Patients
  • Abstract Number: 1470
    Cartilage Epigenetic Changes Induced by Microbial DNA Amplified from Human OA Samples
  • Abstract Number: 0621
    Case Series of IgG4-related Disease in African American Patients at Two Large Academic Centers
  • Abstract Number: 0018
    Caspase-8 Variant G Regulates Rheumatoid Arthritis Fibroblast-Like Synoviocyte Aggressive Behavior
  • Abstract Number: 1565
    Causal Mediation Analysis of the Relationship of Canakinumab’s Protective Effect Against Gout Flares and High-sensitivity C-reactive Protein in the CANTOS Trial
  • Abstract Number: 0429
    Causes and Characteristics of Death in ANCA-Associated Vasculitis – A Large, Real-Life, Contemporary Cohort Analysis
  • Abstract Number: 1032
    Causes of Death Among Populations with Systemic Lupus Erythematosus by Race and Ethnicity
  • Abstract Number: 0049
    CC-99677, a Novel, Selective, Oral MK2 Inhibitor, Sustainably Reduces Pro-inflammatory Cytokine Production and Ameliorates Inflammation in the Mannan-Induced Murine Model of Psoriasis and Psoriatic Arthritis
  • Abstract Number: 0489
    CC-99677: A Novel, Oral, Selective MK2 Inhibitor with Sustainable Multi-Cytokine Inhibition for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
  • Abstract Number: 0459
    CCN1: An Angiogenic Actor Implicated in the Structural Damages of Rheumatoid Arthritis
  • Abstract Number: 1905
    CD11c+ Expression Associates with IFN-λ Responsiveness in Human B Cells with Clinical Implications for SLE
  • Abstract Number: 1479
    CD14, a Toll-like Receptor Co-Factor, Influences Osteoclast Differentiation and Activity, but Does Not Alter Osteoblastic Potential of Bone-Marrow Precursors in Mice
  • Abstract Number: 1005
    CD209/CD14+ Dendritic Cells Characterization in Rheumatoid and Psoriatic Arthritis Patients: Activation, Synovial Infiltration and Therapeutic Targeting
  • Abstract Number: 0703
    CD8 Positron Emission Tomography (PET/CT) Imaging with 89Zr-Df-IAB22M2C in Patients with Inclusion Body Myositis
  • Abstract Number: 0868
    Cell-bound Complement Activation Products (CB-CAPs) Predicts Type 1 SLE Activity
  • Abstract Number: 1890
    Cellular Origin and Functions of Osteoclasts in Inflammatory Arthritis
  • Abstract Number: 0307
    Cerebellar Ataxia in Primary Sjogren’s Syndrome, Is Gluten Sensitivity the Answer?
  • Abstract Number: 0133
    Cervical Cancer Screening Rate in Women with Systemic Lupus Erythematosus
  • Abstract Number: 1720
    Cervical Dysplasia and HPV Infection in Women with Vasculitis
  • Abstract Number: 0609
    Challenges of Caring for Patients with Inflammatory Arthritis Experiencing Homelessness: Preliminary (12- Month) Follow-up Observations and Identification of Certain Barriers to Care
  • Abstract Number: 1596
    Changes in Patient-Reported Outcome (PRO) Scores During the COVID-19 Pandemic: Data from the ArthritisPower Research Registry
  • Abstract Number: 1664
    Changes in Physical Function Were Not Associated with Clinically Important Changes in Muscle Strength or Physical Performance over Time – A Cohort Study
  • Abstract Number: 1473
    Chaperone-mediated Autophagy Is a Hallmark of Joint Damage in Osteoarthritic Patients
  • Abstract Number: 1368
    Characterising Exercise Capacity in Systemic Sclerosis Using Cardiac Magnetic Resonance Imaging, Skeletal Muscle Imaging and Cardiopulmonary Exercise Testing
  • Abstract Number: 1099
    Characteristics and Outcomes of Myocardial Infarction in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Gout and Osteoarthritis Patients Using the National Inpatient Sample Database from 2002-2018
  • Abstract Number: 0866
    Characteristics Associated with Poor COVID-19 Outcomes in People with Systemic Lupus Erythematosus (SLE): Data from the COVID-19 Global Rheumatology Alliance (GRA)
  • Abstract Number: 0094
    Characteristics Associated with Severe Outcomes in Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 in New York City
  • Abstract Number: 1245
    Characteristics of RA Patients Treated with JAK Inhibitors Before versus After VTE Warnings: Results of a Real-World Multicentric Study
  • Abstract Number: 1472
    Characterization and Function of Tumor Necrosis Factor α and Interleukin-6–Induced Osteoclasts in Rheumatoid Arthritis
  • Abstract Number: 1871
    Characterization of Symptoms of Nasal Disease in Relapsing Polychondritis Using Patient-Reported Data
  • Abstract Number: 1407
    Characterization of Synovial Fluid T Cells in Polymyalgia Rheumatica: Implication of Th1 and Tc1 Effector Memory Profiles
  • Abstract Number: 1056
    Characterization of the Patterns of Care, Access and Direct Costs of Systemic Lupus Erythematosus in Brazil: Findings from the Macunaíma Study
  • Abstract Number: 0066
    Characterization of αβTCR of HLA-B*27-Restricted CD8 T-Cell Clones Associated with Spondyloarthropathies
  • Abstract Number: 1784
    Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas’ Psoriasis Registry
  • Abstract Number: 1272
    Characterizing Patient and Physician Perceptions of Systemic Lupus Erythematosus (SLE) Disease Burden Using Traditional Rheumatoid Arthritis Outcomes Measures
  • Abstract Number: 1381
    Chemokines CCL2 and CCL17 as Potential Serum Biomarkers for Interstitial Lung Disease in Systemic Sclerosis
  • Abstract Number: 0203
    Chemoprophylaxis in Latent Tuberculosis Associated with Rheumatic Immune-mediated Diseases. Study of 240 Patients from a Single University Hospital
  • Abstract Number: 1019
    Cigarette Smoking Induces Post-translational Protein Modifications in Both in Vitro and in Vivo Models of Rheumatoid Arthritis-associated Interstitial Lung Disease
  • Abstract Number: 0589
    Circulating Adipokines and Risk of Rheumatoid Arthritis in Women
  • Abstract Number: 0572
    Circulating Cytokines and Chemokines Are Associated with the Risk of Incident Cardiovascular Disease in Rheumatoid Arthritis Independent of Conventional Disease Activity Measures
  • Abstract Number: 1477
    Circulating MicroRNAs in Hand Osteoarthritis
  • Abstract Number: 0997
    Citrullinated Vimentin Induces Epigenetic Memory of the Innate Immune System
  • Abstract Number: 0020
    Citrullination Drives the Expression of Pro-fibrotic Genes in Rheumatoid Arthritis Fibroblast-like Cells
  • Abstract Number: 1756
    Class V Systemic Lupus Erythematosus Nephritis Patients Are Undertreated and Face Similar Adverse Renal Outcomes as Class III/IV Patients
  • Abstract Number: 1282
    Classification of Disease Activity and Damage in Cutaneous Lupus
  • Abstract Number: 1733
    Classification of Patients with Systemic Lupus Erythematosus Enrolled in 2 Phase 3 Trials by EULAR/ACR 2019 Criteria
  • Abstract Number: 0981
    Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
  • Abstract Number: 0130
    Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients: Real World Observation Across Disease Severity and Payer Channels in the U.S
  • Abstract Number: 1107
    Clinical and Genetic Features of Chinese Adult Patients with Chronic Non-bacterial Osteomyelitis: A Single Center Report
  • Abstract Number: 1031
    Clinical and Humanistic Burden of Dermatomyositis and Polymyositis in the United States: A Systematic Literature Review
  • Abstract Number: 1306
    Clinical and Imaging Characteristics of Spondyloarthritis Among Crohn’s Disease Patients
  • Abstract Number: 1357
    Clinical and Molecular Profiles Determining Cardiovascular Risk in Psoriatic Arthritis: Specific Response to Apremilast and Methotrexate
  • Abstract Number: 0873
    Clinical and Serological Characteristics of Latin American Patients with Lupus Enteritis: A Case-Control Study
  • Abstract Number: 1089
    Clinical Associations of Anti-Ro52 Antibodies in Patients with Systemic Autoimmune Rheumatic Diseases
  • Abstract Number: 1813
    Clinical Characteristics & Outcomes Associate with Work Productivity in Bio-naïve Patients with Active Psoriatic Arthritis Through Week 24 of the DISCOVER-2 Study
  • Abstract Number: 1563
    Clinical Characteristics and Management of Olecranon and Prepatellar Septic Bursitis in a Multicenter Study
  • Abstract Number: 0431
    Clinical Characteristics and Outcomes of ANCA-Associated and Non Immune-Mediated Hypertrophic Pachymeningitis: A Comparative Study
  • Abstract Number: 0150
    Clinical Characteristics and Quantitative CT Findings in Connective Tissue Disease-Associated Interstitial Lung Disease
  • Abstract Number: 1882
    Clinical Characteristics and Reliability of a Self-Reported Diagnosis of Large-Vessel Vasculitis
  • Abstract Number: 0699
    Clinical Characteristics of Idiopathic Inflammatory Myositis Manifesting with Myoglobinuria: A 15 Year Retrospective Review
  • Abstract Number: 1625
    Clinical Characteristics of Multisystem Inflammatory Syndrome in Children: A Provincial Cohort
  • Abstract Number: 1298
    Clinical Characteristics of Patients with Pre-pubertal Onset SLE and Disease Outcome Throughout Puberty: A Multicenter North American Longitudinal Study
  • Abstract Number: 1310
    Clinical Characteristics of Patients with SpA and Concomitant IBD: Results from the ASAS PerSpA Study
  • Abstract Number: 0446
    Clinical Characteristics, Including History of Myocardial Infarction and Stroke, Among US PMO Women Initiating Treatment with Romosozumab and Other Anti-osteoporosis Therapies
  • Abstract Number: 1528
    Clinical Consequences of Hepatitis B Core Antibody Positivity After IVIG Administration
  • Abstract Number: 1544
    Clinical Course and Risk Factors for Severe/Critical COVID-19 in Patients with Rheumatic Diseases – a Multicenter, Nationwide Study
  • Abstract Number: 1632
    Clinical Features and Colchicine Response in Patients with Undifferentiated Systemic Autoinflammatory Disease Carrying E148Q vs. Other MEFV Mutations
  • Abstract Number: 0687
    Clinical Features and Prognosis of a Large North American Cohort of Adult MDA5+ Dermatomyositis
  • Abstract Number: 1409
    Clinical Features at Disease Onset of Different Subsets of Large-vessel-giant Cell Arteritis in a Monocentric Cohort of 100 Patients
  • Abstract Number: 1457
    Clinical Heterogeneity of the VEXAS Syndrome: A Case Series
  • Abstract Number: 0122
    Clinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management: A Randomized Controlled Trial
  • Abstract Number: 1638
    Clinical Manifestations of COVID-19 and Its Impact on Pediatric Patients with Rheumatic Disease
  • Abstract Number: 1278
    Clinical Outcomes in a Cohort of Puerto Ricans with Systemic Lupus Erythematosus After SARS CoV-2 Infection
  • Abstract Number: 0700
    Clinical Outcomes in Idiopathic Inflammatory Myositis Within the Military Health System: A 15 Year Retrospective Review
  • Abstract Number: 1555
    Clinical Outcomes of Coronavirus Disease-2019 (COVID-19) in Hospitalized Patients with Rheumatic and Musculoskeletal Diseases (RMD)
  • Abstract Number: 1710
    Clinical Outcomes of MTX-Naïve RA Patients on Filgotinib Long-term Extension Trial Initially on FIL or MTX During Phase 3 Parent Trial
  • Abstract Number: 0092
    Clinical Outcomes of Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 at a Large Academic Center in New York City
  • Abstract Number: 1697
    Clinical Outcomes up to Week 48 of Filgotinib Treatment in an Ongoing Long-term Extension Trial of RA Patients with Inadequate Response to MTX Initially Treated with Filgotinib or Adalimumab During the Phase 3 Parent Trial
  • Abstract Number: 1696
    Clinical Outcomes up to Week 48 of Ongoing Filgotinib RA Long-term Extension Trial of Biologic DMARD Inadequate Responders Initially on Filgotinib or Placebo in a Phase 3 Trial
  • Abstract Number: 1516
    Clinical Phenotypes and Treatment of Rheumatic Immune-Related Adverse Events from Checkpoint Inhibitors: A Retrospective Cohort of 112 Patients
  • Abstract Number: 0500
    Clinical Phenotypes of Patients with Systemic Sclerosis with Distinct Molecular Signatures in the Skin
  • Abstract Number: 1227
    Clinical Predictors of Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach Using Clinical Trial Data
  • Abstract Number: 1757
    Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: A Case Series
  • Abstract Number: 1402
    Clinical, Laboratory and Imaging Outcomes in Tocilizumab-Treated Patients with Large Vessel-Giant Cell Arteritis According to Early Onset Therapy
  • Abstract Number: 0003
    Clinically Identifiable Autoreactivity Is Common in Severe SARS-CoV-2 Infection
  • Abstract Number: 1862
    Clonal Hematopoiesis Across the Age Spectrum in Patients with Systemic Vasculitis
  • Abstract Number: 1358
    Clusters of Psoriatic Arthritis Patients at Baseline Based on Different Ultrasound Detected Synovitis: Exploratory Analysis from a Phase III Study
  • Abstract Number: PP06
    Collaborative Advocacy Helps Me and Other Patients With Relapsing Polychondritis (“RP”’) /  My life improved by helping the RP Foundation and Race for RP facilitate awareness, education, and research to improve the quality of life for patients with RP and advance a cure for this disease.
  • Abstract Number: 1076
    Combining Fuzzy Logic with Time-Driven Activity Based Costing Within the Rheumatoid Arthritis Care Cycle: Insights from a Dutch Hospital
  • Abstract Number: 1102
    Comorbidities and Causes of Hospitalizations in a Cohort of IgG4-Related Disease Patients from a Single Center
  • Abstract Number: 0577
    Comorbidity Burden as Scored Using the Rheumatic Disease Comorbidity Index (RDCI) Is Associated with Varying Treatment Patterns in Patients with Inflammatory Arthritis – a Study Using the EHR-Derived Rheumatic and Arthritis Disease Information Registry (RADIR)
  • Abstract Number: 1346
    Comparable Safety Profile of Guselkumab in Psoriatic Arthritis and Psoriasis: Results from Phase 3 Trials Through 1 Year
  • Abstract Number: 1654
    Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL
  • Abstract Number: 0938
    Comparative Effectiveness and Treatment Survival of Different TNF Inhibitors for Axial Spondyloarthritis in Real-World Clinical Practice
  • Abstract Number: 0834
    Comparative Effectiveness of TNF Inhibitor vs IL-6 Receptor Inhibitor as Monotherapy or Combination Therapy with Methotrexate in Patients with Rheumatoid Arthritis: Analysis from CorEvitas’ RA Registry
  • Abstract Number: L06
    Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach
  • Abstract Number: 1870
    Comparative Study on Anti-TNF vs Tocilizumab for Treatment of Refractory Uveitic Cystoid Macular Edema Due to Behcet’s Disease: Multicenter Study of 49 Patients
  • Abstract Number: 0839
    Comparative Treatment Effectiveness in Rheumatoid Arthritis with and Without Concomitant Sjögren’s Syndrome – Results from the Swiss Clinical Quality Management Cohort
  • Abstract Number: 1061
    Comparing Consultation Patterns Across Telehealth Platforms and Face-to-Face Clinic in the Military Health System
  • Abstract Number: 1773
    Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from DISCOVER 1&2 and PSUMMIT Trials
  • Abstract Number: 0135
    Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression
  • Abstract Number: 1802
    Comparison of Axial and Peripheral Manifestations in Patients with Psoriatic Arthritis and Ankylosing Spondylitis in Upadacitinib Clinical Trials
  • Abstract Number: 1761
    Comparison of Belimumab and Standard of Care by Inverse Probability of Treatment Weighting Analyses Based on Propensity Score in Patients with Systemic Lupus Erythematosus in the Maintenance Phase
  • Abstract Number: 1817
    Comparison of Composite Indices for Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib: A Post-Hoc Analysis from SELECT-PsA 1
  • Abstract Number: 0378
    Comparison of Demographic, Clinic and Radiological Features of Axial Spondyloarthritis Patients with and Without Accompanying Familial Mediterranean Fever
  • Abstract Number: 1109
    Comparison of Diagnostic Criteria in Behçet’s Disease and Sensitivity in Diagnosing Severe Manifestations
  • Abstract Number: 0294
    Comparison of Factors Associated with CT-Scan Progression of Interstitial Lung Disease in Rheumatoid Arthritis and Idiopathic Pulmonary Fibrosis. Retrospective Multicenter Study of 144 Patients
  • Abstract Number: 1533
    Comparison of Hospitalization and Mortality Rate in Patients with Different Rheumatic Diseases: A Brazilian Registry Cross-Sectional Analysis
  • Abstract Number: 0899
    Comparison of Sacroiliac CT Findings in Patients with and Without Ankylosing Spondylitis Aged 50 Years or Older: Preliminary Results of the CASIAGE Study
  • Abstract Number: 1241
    Comparison of the Effects of Upadacitinib Monotherapy with MTX on Protein Biomarkers in MTX-Naïve and MTX-Inadequate Responders in Patients with Active Rheumatoid Arthritis: Results from the SELECT-EARLY and SELECT‑MONOTHERAPY Phase 3 Studies
  • Abstract Number: 0869
    Comparison of Two Frailty Definitions in Women with Systemic Lupus Erythematosus
  • Abstract Number: 1574
    Comparison of Urate Quantification in Gout and Asymptomatic Hyperuricemia by Ultrasound and Dual Energy Computed Tomography
  • Abstract Number: 1370
    Complement Factor D and Factor H Represent Disease and Severity Biomarkers for Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
  • Abstract Number: 1208
    Composite Articular Index Including Acute Phase Reactants Should Not Be Used in Patients with Rheumatoid Arthritis Treated with Il6 Inhibitors but May Be Useful in Those Receiving Jak Inhibitors: Ultrasound Evidence
  • Abstract Number: 1045
    Composition of Phospholipid Fatty Acids in Erythrocyte Membranes from Patients with Ankylosing Spondylitis
  • Abstract Number: 1657
    Comprehensive Assessment of Multimorbidity Burden in a Population-based Cohort of Patients with Rheumatoid Arthritis
  • Abstract Number: 1595
    Concern About the COVID-19 Pandemic and Community Mobility Among Systemic Lupus Erythematosus Patients
  • Abstract Number: 0617
    Concerns and Beliefs About COVID-19 Vaccination Among Racial and Ethnic Minority Patients with Rheumatic Disease
  • Abstract Number: 0671
    Concomitant Immunomodulation and Pegloticase Therapy: Experiences with a Variety of Immunomodulatory Agents in Two Community Rheumatology Practices
  • Abstract Number: 1519
    Concomitant Targeted Therapy with Ongoing Immune Checkpoint Inhibitor (ICI) Therapy for Severe Immune Related Adverse Events (irAEs): Clinical Experience from Two Centers
  • Abstract Number: 0854
    Confirmatory Factor Analysis of the Fatigue Assessment Instrument and Fatigue Severity Scale in Systemic Sclerosis
  • Abstract Number: 0256
    Consensus Approach to a Treat to Target Strategy in Juvenile Idiopathic Arthritis Care: Report from the 2020 Pediatric Rheumatology Care and Outcomes Improvement Network Consensus Conference
  • Abstract Number: 0832
    Consistency in Time to Response with Upadacitinib as Monotherapy or Combination Therapy and Across Patient Populations with Rheumatoid Arthritis
  • Abstract Number: 1863
    Consistent Efficacy with Apremilast in Men and Women to Treat Oral Ulcers Associated with Behçet’s Syndrome: Results from Phase 3 Researching Oral Apremilast Safety and Efficacy in Behçet’s Disease (RELIEF) Study
  • Abstract Number: 1231
    Consistent Impact of Autoantibody Enrichment Across All ACR Core Measures in Early Rheumatoid Arthritis Treated with Abatacept: Data from a Large Pooled Analysis of 4 Randomized Controlled Trials
  • Abstract Number: 1731
    Construction and Validation of a Reproductive Health Questionnaire for Women with Rheumatic Diseases
  • Abstract Number: 0568
    Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD)
  • Abstract Number: 0739
    Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)
  • Abstract Number: 0186
    Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases: Data from INBUILD-ON
  • Abstract Number: 1850
    Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Two-Year Data from SENSCIS-ON
  • Abstract Number: 0636
    Contraceptive and Pre-conception Counseling in an Academic Rheumatology Practice: A Needs Assessment to Identify Gaps in Care
  • Abstract Number: 0793
    Contributing Factors of Good Outcome in Difficult-to-treat Rheumatoid Arthritis: A Multicenter RA Ultrasound Prospective Observational Cohort Study in Japan
  • Abstract Number: 1090
    Contribution of Scleroderma/Myositis-Related Antibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 134 Patients from a Single Referral Center
  • Abstract Number: 1513
    Control of T Cell Tolerance by the NR4A Family of Nuclear Receptors
  • Abstract Number: 0529
    COPA Syndrome-associated Mutations in Lung Transplant Recipients for Interstitial Lung Disease
  • Abstract Number: 0806
    Coping with Recent-onset Rheumatoid Arthritis (RA): Validation of the Coping with Health Injuries and Problems (CHIP) Questionnaire in a Longitudinal Cohort
  • Abstract Number: 0318
    Correlation Between Prognostic Nutritional Index and Primary Sjögren’s Syndrome Disease Activity
  • Abstract Number: 0635
    Correlation Between Provider Documentation and Patient Experience with Contraceptive Counseling in an Academic Rheumatology Practice
  • Abstract Number: 0634
    Correlation Between the Functional Component of the Multidimensional Health Assessment Questionnaire (FN), Modified Health Assessment Questionnaire (MHAQ), Health Assessment Questionnaire II (HAQ-II) and a Single Functional Question (PF) in Patients with Rheumatic Disease
  • Abstract Number: 0474
    Correlation of Fibromyalgia Survey Questionnaire and Quantitative Sensory Testing Among Patients with Active Rheumatoid Arthritis
  • Abstract Number: 0175
    Correlation of Subclinical Synovitis with Juvenile Idiopathic Arthritis Outcome Measurements
  • Abstract Number: 1812
    Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 DISCOVER Program
  • Abstract Number: 0465
    Cost-effectiveness of Treatment Strategies Involving Arthroscopic Partial Meniscectomy and Physical Therapy for Degenerative Meniscal Tear
  • Abstract Number: 1129
    Cost-effectiveness of Weight Loss Interventions Prior to Total Knee Replacement for Patients with Advanced Knee Osteoarthritis and Class III Obesity
  • Abstract Number: 1085
    COVID 19 Infection in Patients with Rheumatic Immune-mediated Diseases in a Single University Hospital: Matched Case-control Study
  • Abstract Number: 1084
    COVID-19 Among Patients with Inflammatory Arthropathies Participating in the RHUMADATA Clinical Database and Registry
  • Abstract Number: 0882
    COVID-19 Impact Among Patients with Systemic Lupus Erythematosus
  • Abstract Number: 1671
    COVID-19 in Patients with Rheumatoid Arthritis Compared to Patients with Osteoarthritis During the Pandemic in New York City
  • Abstract Number: 1452
    COVID-19 Infection Among Autoimmune/Auto-inflammatory Rheumatic Disease Patients: Data from an Observational Study
  • Abstract Number: 1637
    Covid-19 Infection Among Pediatric Rheumatology Patients: A Single Center Experience
  • Abstract Number: 0109
    COVID-19 Infection and Outcomes in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis
  • Abstract Number: 0106
    COVID-19 Mortality and Hospitalization Risk in Patients with Rheumatic Diseases: A Single Center Retrospective Cohort Study
  • Abstract Number: 0116
    COVID-19 mRNA Vaccine Side Effects Among Individuals with Rheumatic Disease
  • Abstract Number: 1594
    COVID-19 Pandemic-Related Changes in Health Routines and Self-Reported Physical Functioning Among Systemic Lupus Erythematosus Patients
  • Abstract Number: 0084
    COVID-19 Pneumonia in Two Hospitals: Similar Outcomes Despite Differential Use of Tocilizumab
  • Abstract Number: 1603
    COVID-19 Vaccination Experience in Patients with Rheumatoid Arthritis Treated at the Cleveland VA Medical Center
  • Abstract Number: 0444
    COVID-19 Vaccination in Autoimmune Disease (CoVAD) Study: Interim Analysis of Safety in Idiopathic Inflammatory Myopathies from a Large Multicentre Global Survey
  • Abstract Number: 1524
    COVID-19 Vaccination Rates and Adverse Events Among Patients on Immunosuppressive Therapy in the Rheumatology Clinic Caring for an Underserved Population
  • Abstract Number: L03
    COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine
  • Abstract Number: 1554
    COVID-19 Vaccine Hesitancy Among Patients with Rheumatic and Other Diseases
  • Abstract Number: 1589
    COVID-19 Vaccine Hesitancy in Rheumatology Patients
  • Abstract Number: L02
    COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
  • Abstract Number: PP13
    CreakyKitchen: How the Online Cooking Show I Started is Building Community and Encouraging Better Food Choices for Me and Others Living with Rheumatic and Chronic Disease
  • Abstract Number: 1583
    Creation of an Ultrasonographic Scoring System for CPPD Extent: Results from a Delphi Process by the OMERACT US Working Group – CPPD Subgroup
  • Abstract Number: 1030
    Critical Illness in Modern Rheumatology: Analysis of Admissions to Australian and New Zealand ICUs
  • Abstract Number: 1110
    Cryopyrin-associated Periodic Syndromes: GOSH and National Amyloidosis Centre Experience
  • Abstract Number: 1096
    CSF-specific CD8 T Cell Clonal Expansion in Neurosarcoidosis
  • Abstract Number: 0976
    Cumulative Social Disadvantage Predicts an Arthritis Diagnosis: A Cross-sectional Analysis of the National Survey of Children’s Health (NSCH)
  • Abstract Number: 1810
    Current Medication Practices and Preferences Among Patients with Psoriatic Arthritis (PsA)
  • Abstract Number: 1204
    CXCL13 Outranges DAS28CRP and CRP as Predictor of Long-term Radiographic Status in Early Rheumatoid Arthritis
  • Abstract Number: 1767
    CXCL5 Dampens Inflammation in Murine Lupus by Orchestral Suppression of Effector Cell Proliferation and Leukocyte Extravasation
  • Abstract Number: 0013
    Cyclin Dependent Kinase 4 and 6 Determine the Cytokine Responsiveness by Stabilizing JUN in Rheumatoid Arthritis Synovial Fibroblasts
  • Abstract Number: 0947
    Cytokine Competent Gut-joint Migratory T Cells Contribute to Inflammation in the Joint
Jump to:  View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology